Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024
Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL.
Cytokinetics公司（纳斯达克：CYTK）今天宣布，新数据显示了GALACTIC-HF的事后分析结果（全球货币降低心脏不良结果的方法，通过改善心力衰竭的收缩力），该项针对omecamtiv mecarbil的三期心血管临床试验的结果在2024年美国心脏协会科学会议上公布，地点在伊利诺伊州芝加哥。
"These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher risk, such as older patients or those with a recent ventricular arrhythmia," said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. "As we prepare for the start of COMET-HF, the confirmatory Phase 3 clinical trial of omecamtiv mecarbil, we look forward to evaluating its potential to reduce the risk of adverse heart failure outcomes across the spectrum of these very high-risk patients failing guideline-directed medical therapy."
“这些分析巩固了omecamtiv mecarbil在GALACTIC-HF中高风险患者（如年长患者或近期经历心室心律失常患者）中的潜在治疗利益，”首席医疗官、资深副总裁Stuart Kupfer万.D.表示。“在我们为开始控件COMEt-HF，omecamtiv mecarbil的确认性三期临床试验而做准备时，我们期待评估其降低这些高风险患者心力衰竭不良结果风险的潜力，这些患者都在接受指南指导的医疗治疗。”
热门市场机会
热门讨论
热门讨论
